Teva Pharmaceutical Industries Limited (TEVA) key performance indicators and operating metrics (87 metrics) from SEC EDGAR filings, earnings calls, and investor decks. First-party data.
| Metric | Latest Value | Period |
|---|---|---|
| Key innovative brands revenue growth | 41.00 percent | FY2026-Q1 |
| Europe segment revenue | 1.26B | FY2026-Q2 |
| International Markets segment revenue | 550M | FY2026-Q2 |
| Non-GAAP operating income | 375M | FY2026-Q2 |
| Non-GAAP net income attributable to Teva | 621M | FY2026-Q1 |
| Non-GAAP diluted earnings per share | 0.53 USD_per_share | FY2026-Q1 |
| Non-GAAP operating margin | 9.00 percent | FY2026-Q2 |
| Free cash flow | 622M | FY2026-Q2 |
| North America AUSTEDO revenue | 559M | FY2026-Q1 |
| United States segment revenue | 1.7B | FY2026-Q2 |
| UZEDY revenue | 77M | FY2026-Q2 |
| AJOVY global revenue | 244M | FY2026-Q2 |
| AUSTEDO U.S. revenue | 676M | FY2026-Q2 |
| AUSTEDO global revenue | 696M | FY2026-Q2 |
Back to TEVA overview · TEVA earnings · TEVA holders
Data sourced from U.S. SEC EDGAR filings, earnings call transcripts, and investor decks. Not personalized investment advice.